NEW DELHI: In a development that could substantially benefit Indian companies, the US is moving closer to opening up the world’s largest pharmaceutical market for generic versions of blockbuster MNC biotech drugs. A US Senate panel has cleared a landmark bill which will allow drug makers to sell generic versions of biotech medicines in the $60-billion US biotech market after 12 years of exclusive marketing rights by the innovator company.
